Cancer start-up receives US$16m funding

QUE Oncology, a clinical-stage biotechnology company established by The University of Queensland and Emory University (Atlanta, USA), has received US$16 (AU$20.99) million in series A investment.

The investment from the Brandon Capital-managed Medical Research Commercialisation Fund (MRCF) and Uniseed will enable the company to further develop novel cancer supportive care and anticancer therapies.

Read more

Innovative local projects receive boost in latest funding round

FOUR innovative local science and innovation projects in the Gisborne-East Coast district are sharing grants totalling $340,000 in the 2017 Te Panaha Hihiko – Vision Matauranga Capability Fund investment round.

This is the fifth round for the fund, managed by the Ministry of Business, Innovation and Employment, which was established to grow skills and capacity for Maori participation in science and innovation, and support outcomes that benefit New Zealand.

Read more

Victoria set for new fintech hub that will “send a strong signal” to the rest of the world

Victoria will seek to position itself as a major international player in the fintech sector, with the state government last week unveiling plans for a new hub in Melbourne’s Docklands precinct to boost jobs and encourage startups in this fast growing industry.

The hub will be housed in the Goods Shed North in Docklands and will bring together startups, corporates and researchers under one roof.

Read more

Brexit a huge opportunity for New Zealand companies

New Zealand agri-businesses are in a position to step up trade and investment in the United Kingdom after its decision to exit the European Union.

The Brexit vote had made it clear how important free trade was going to be for the UK over the next 10-20 years and was why the UK Department of International Trade was back at Fieldays for the first time in 17 years, British High Commissioner Jonathan Sinclair said.

Read more

Private equity, capital flows bolster local 2017 M&A prospects

Local bankers and lawyers expect a strong final half for mergers and acquisitions, after a jump in activity and resurgence in private equity-led deals so far this year.

Those canvassed by The Australian Financial Review said the pipeline of M&A deals was healthy, and buoyed by large pools of global capital that had to be deployed and favourable funding markets. They expect a strong rather than stellar finish to 2017.

Read more

Canada Is Using Genetics to Make Cows Less Gassy

Number 1995 is a very special cow. Every day, this Holstein, mostly black with a white cat-face-shaped spot on her forehead, sticks her head into a trough that measures the exact amount of feed she eats. She’s had her genome partially sequenced, and will soon get her breath checked for methane several times a day.

Number 1995 also happens to be J. P. Brouwer’s favorite. “I just like her character,” the Canadian farmer says. “It has nothing to do with how she looks. She’s a nice cow.”

Read more

Urine to power Glastonbury festival displays

The lavatory facilities at festivals can often be feared as pits of despair, but a team of scientists are set to turn Glastonbury goers’ wee into energy.

Display boards at this year’s Glastonbury festival are going to be powered by urine, provided via a 40-person urinal which will be situated near to the headline Pyramid stage.

Read more

CSL makes $466m Chinese plasma play

AUSTRALIAN biotechnology titan CSL has secured a foothold in the world’s fastestgrowing plasma products market, snaring a majority stake in Chinese group Ruide.

CSL has agreed to pay $US352 million ($466 million) for 80 per cent of the Chinese biotech from Shanghai-based Humanwell Healthcare. The deal will give the vaccines and blood products supplier access to China’s plasma products market, which was valued at more than $3.3 billion last year and is tipped to grow about 15 per cent a year.

Read more

Competition Commission on investigation into cancer drugs manufacturers

As you may be aware, the Competition Commission has identified the healthcare sector, and in particular, pharmaceuticals, as a priority sector for its enforcement efforts due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable.


Read more